Tempus AI is strengthening its position in minimal residual disease (MDR) testing with the proposed $1.5 billion acquisition of Personalis. The deal is expected to close in late 2026 or early 2027.

Regulatory expert Jessica Schafersman explains why device startups must integrate FDA compliance from concept phase, not ...

Vital Signals has launched Signal Ring, the first wearable ring designed specifically for continuous, calibration-free blood ...

Intuitive Surgical's greatest headwinds stem not from competitors in the surgical robotics market but from the rising use of ...

Aziz Mottiwala becomes RxSight CEO July 20 amid commercial challenges. The move follows the $200M Alcon deal for adjustable ...

DePuy Synthes has acquired Expanding Innovations, a startup specializing in expandable implant technology for spine surgeries ...

Vicarious Surgical’s board is asking shareholders to approve a plan that would dissolve the financially strapped company, ...

Dinneen breaks down the biggest networking mistake that medtech professionals make — and how to fix it. Below is a transcript ...

A third-party randomized trial from King’s College London is being cited as the reason Johnson & Johnson’s Impella usage has ...

The post-MDR insourcing wave left teams stretched. See why MedTech leaders now treat compliance consulting as a strategic ...

EU-Mexico trade deal eliminates tariffs on medical devices, helping Mexico's $22B medtech sector diversify beyond U.S. market ...

Tube wall thickness and concentricity are among the most critical quality attributes in extruded medical tubing. Variation in ...